Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2024
0mins
Source: Newsfilter
Clinical Trial Resumption: Kineta, Inc. has resumed patient enrollment in its VISTA-101 Phase 1/2 clinical trial for KVA12123, following a previous suspension due to funding issues. The company aims to complete enrollment by the end of 2024.
Partnership and Development: Kineta entered an agreement with TuHURA Biosciences, receiving a $5 million payment, to collaborate on the trial and further develop KVA12123, which shows promise as an immunotherapy for various cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
